NCT01900002View on ClinicalTrials.gov

Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 13, 2013

Primary Completion Date

December 10, 2020

Study Completion Date

December 10, 2020

Conditions
Advanced Adult Hepatocellular CarcinomaBCLC Stage C Hepatocellular CarcinomaRecurrent Adult Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v7Stage IIIA Hepatocellular Carcinoma AJCC v7Stage IIIB Hepatocellular Carcinoma AJCC v7Stage IIIC Hepatocellular Carcinoma AJCC v7Stage IV Hepatocellular Carcinoma AJCC v7Stage IVA Hepatocellular Carcinoma AJCC v7Stage IVB Hepatocellular Carcinoma AJCC v7Unresectable Hepatocellular Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

DRUG

Sorafenib

Given PO

DRUG

Sorafenib Tosylate

Given PO

RADIATION

Yttrium Y 90 Glass Microspheres

Given IA

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01900002 - Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter